

FDA Panel: Physicians Key in DTC Genetic Tests

BY ALICIA AULT

FROM THE FDA'S MOLECULAR AND CLINICAL GENETICS ADVISORY COMMITTEE MEETING

GAITHERSBURG, MD. – The Food and Drug Administration should require that genetic tests sold directly to consumers should in some cases be ordered by a trained health care professional, and that such professionals should interpret results of most of these tests, an advisory committee to the agency has urged.

The panel did not take any formal votes during the meeting, but discussed a variety of issues related to tests that are currently sold, almost without any regulation, to consumers over the Internet. Last year, the FDA notified manufacturers of such tests that they must comply with agency rules, and the agency is working with companies now to help them win approval.

The tests run the gamut from diagnostics that determine carrier status for diseases like cystic fibrosis, to those that test for the presence of a specific muta-

Test makers and the consumer member of the panel said that Americans have the right to their own genetic data, and that in all likelihood, consumers would consult with a physician.

tion like BRCA or assess the risk of developing cardiovascular disease or certain cancers. A number of tests on the market have no scientific evidence to substantiate their claims for being able to predict outcomes such as whether a child will excel at sports.

In July 2010, the agency estimated that as many as 700 laboratories offer such direct-to-consumer (DTC) genetic tests.

During the course of the 2-day meeting, the 22 committee members struggled over whether the benefits of consumers' having access to such data outweigh the risks of their being unable to understand the results, or perhaps their becoming falsely reassured or upset by them. The panelists gave the agency some suggestions on how the risks of poor communication or bad test design could be mitigated.

But most of the debate centered on the role of physicians or trained health care professionals, and most of the panelists believed that professionals should be centrally involved at some point in the process. Test makers and the consumer member of the panel, for their part, said that Americans have the right to their own genetic data, and that in all likelihood, consumers would consult with a physician, especially if it were for a serious condition such as Huntington's disease.

"As a patient, if I got a test result like that, I'd take it to my doctor," said Tiffany House, the panelist's consumer

representative. "I'd think they'd probably run to their doctor with this information," said Ms. House, who is a board member of the International Pompe Association.

After the meeting, FDA officials acknowledged that there was no real consensus on what role physicians should play. "We got lots of diverse advice," said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostic Device

Evaluation and Safety at the FDA's Center for Devices and Radiological Health.

He said that the agency would likely have to review each genetic test to determine whether it should be directly available to a consumer, and if so, whether a physician should order it or receive results directly. With so many opinions expressed, it may take awhile for things to settle out, said Elizabeth Mansfield, Ph.D., director of the personal-

ized medicine staff in that same CDRH office. "We need to digest what came out of this meeting."

The FDA usually follows its panels' advice, but is not required to do so.

The FDA asked the panel to assess five test categories (carrier tests, "pre-symptomatic" tests, susceptibility tests, pharmacogenetic tests, and nutrigenetic tests). The agency wanted to know whether some categories should be

An advance in the treatment of postmenopausal osteoporosis



Atelvia™ is a bisphosphonate in a delayed-release formulation and is indicated for the treatment of osteoporosis in postmenopausal women.

Selected Safety Information for Atelvia™ (risedronate sodium) delayed-release tablets

Atelvia™ is contraindicated in patients with an inability to stand or sit upright for at least 30 minutes, hypocalcemia, abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia, or known hypersensitivity to any component of this product. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Atelvia™ therapy. Atelvia™ is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min).

Atelvia™ should be taken in the morning immediately following breakfast. The optimal duration of therapy has not been determined. Patients should have the need for continued

therapy re-evaluated on a periodic basis. Atelvia™ and Actonel® (risedronate sodium) contain the same active ingredient and therefore, should not be used concurrently.

Atelvia™, like other bisphosphonates administered orally, can cause local irritation of the upper gastrointestinal (GI) mucosa, sometimes severe. Esophageal adverse experiences, such as esophagitis, esophageal ulcers and esophageal erosions, occasionally with bleeding and rarely followed by esophageal stricture or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. Dosing instructions should be followed and caution should be used in patients with upper GI disease. Discontinue use if new or worsening symptoms occur.

There have also been reports of severe and occasionally incapacitating bone, joint and/or muscle pain in patients taking bisphosphonates. Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported in bisphosphonate-treated patients. Causality has not been established as these

classified as lower or higher risk and thus be subject to more regulatory restrictions.

The panel did not feel comfortable with the selling of carrier tests (that is, those that identify cystic fibrosis, Tay-Sachs disease, and other conditions) directly to consumers.

"Many of these disorders have a spectrum of communication that can't be well communicated outside of clinical consultation," said panelist Ira Lubin, Ph.D., a clinical molecular geneticist at the Centers for Disease Control and Prevention.

For tests that assess the risk of common conditions such as cancer, Alzheimer's, or cardiovascular disease, the panel was concerned that the results might be falsely reassuring or might discount environmental or lifestyle factors that might also contribute to risk.

"I don't think any of us are saying the patient or the consumer doesn't have a right to know," said panelist Joann Boughman, Ph.D., CEO of the American Society of Human Genetics.

"I would suggest we are not ready yet to put this directly into the consumers' hands," he said.

Former FDA official Mary Pendergast, who now works as a food and drug consultant and adviser to some companies that seek to market genetic tests, said that the panel was being paternalistic in its insistence on looking for a way to keep the tests from being sold directly to consumers.

"There is an alternative to this highly paternalistic approach; that information in and of itself is not harmful," said Ms. Pendergast.

A government-sponsored study that was presented at the meeting seemed to back her assertion. The National Hu-

man Genome Research Institute's Multiplex Initiative found that people who underwent tests for eight common diseases were highly satisfied with the results – regardless of what those results showed – and that they felt as if they understood the implications and limitations of the tests.

The 266 people who took the tests tended to have more positive than negative emotions in the wake of receiving results, said Colleen McBride, Ph.D., the study's designer and a senior investigator at the institute's Social and Behavioral Research Branch. ■

Enteric-Coated Atelvia™ for

Efficacy Without the Wait

The only oral bisphosphonate that eliminates the waiting time to eat or drink¹⁻⁴

● **Dosed immediately after breakfast, once weekly¹**

Enteric-Coated
Atelvia™ 35 mg
(risedronate sodium) delayed-release tablets

Efficacy Without the Wait

fractures also occur in osteoporotic patients who have not been treated with bisphosphonates. Patients with new thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femoral fracture.

Osteonecrosis of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including risedronate. Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

Clinical judgment of the treating physician and/or oral surgeon should guide the management plan (including the consideration of discontinuation of bisphosphonate therapy) of each patient based on individual benefit/risk assessment.

Most common adverse reactions reported in >5% of patients treated with Atelvia™ include: diarrhea, influenza, arthralgia, back pain, and abdominal pain. Hypersensitivity reactions (angioedema, generalized rash and bullous skin reactions, some severe), and eye inflammation (iritis, uveitis) have been reported rarely.

References: 1. Atelvia™ [package insert]. Rockaway, NJ: Warner Chilcott (US), LLC; January 2011. 2. Boniva® [package insert]. South San Francisco, CA: Genentech USA, Inc.; January 2011. 3. Fosamax® [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; January 2011. 4. Actonel® [package insert]. Rockaway, NJ: Warner Chilcott (US), LLC; February 2011.

Please see Brief Summary of Full Prescribing Information on the following page. Please see Full Prescribing Information, which includes the Medication Guide, at www.atelvia.com.

Atelvia™ is a trademark of Warner Chilcott Company, LLC.

Actonel® is a registered trademark of Warner Chilcott Company, LLC.

